Tempest Therapeutics earnings were -$44.8M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest TPST earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$10.9M, down 21.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, TPST reported annual earnings of -$41.8M, with 41.9% growth.
Tempest Therapeutics Earnings Reports & History FAQ
What were Tempest Therapeutics's earnings last quarter?
On TPST's earnings call on Invalid Date, Tempest Therapeutics (NASDAQ: TPST) reported Q1 2025 earnings per share (EPS) of -$3.16, up 31.6% year over year. Total TPST earnings for the quarter were -$10.86 million. In the same quarter last year, Tempest Therapeutics's earnings per share (EPS) was -$4.62.
Is Tempest Therapeutics profitable or losing money?
As of the last Tempest Therapeutics earnings report, Tempest Therapeutics is currently losing money. Tempest Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$44.80 million, a 50.54% increase year over year.
What was TPST's earnings growth in the past year?
As of Tempest Therapeutics's earnings date in Invalid Date, Tempest Therapeutics's earnings has grown year over year. TPST earnings in the past year totalled -$44.80 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.